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Biocompatibility of phosphorylcholine coated
stents in normal porcine coronary arteries
D M Whelan, W J van der Giessen, S C Krabbendam, E A van Vliet, P D Verdouw,
P W Serruys, H M M van Beusekom
Abstract
Objective—To improve the biocompatibility of stents using a phosphorylcholine coated stent as
a form of biomimicry.
Interventions—Implantation of phosphorylcholine coated (n = 20) and non-coated (n = 21)
stents was performed in the coronary arteries of 25 pigs. The animals were killed after five days
(n = 6), four weeks (n = 7), and 12 weeks (n = 8), and the vessels harvested for histology, scan-
ning electron microscopy, and morphometry.
Main outcome measures—Stent performance was assessed by studying early endothelialisa-
tion, neointima formation, and vessel wall reaction to the synthetic coating.
Results—Stent thrombosis did not occur in either group. Morphometry showed no significant
diVerences between the two study groups at any time point. At five days both the coated and
non-coated stents were equally well endothelialised (91% v 92%, respectively). At four and 12
weeks there was no diVerence in intimal thickness between the coated and non-coated stents. Up
to 12 weeks postimplant the phosphorylcholine coating was still discernible in the stent strut
voids, and did not appear to elicit an adverse inflammatory response.
Conclusion—In this animal model the phosphorylcholine coating showed excellent blood and
tissue compatibility, unlike a number of other polymers tested in a similar setting. Given that the
coating was present up to 12 weeks postimplant with no adverse tissue reaction, it may be a
potential candidate polymer for local drug delivery.
(Heart 2000;83:338–345)
Keywords: phosphorylcholine; stents; coatings; biocompatible materials
Significant advances have been made in the
field of interventional cardiology through the
use of coronary stents. A restenosis rate of
30–50% after balloon angioplasty has been
reduced to a current rate of 10–30% after
stenting. Such a reduction has led to the use of
stents in wider patient populations with
improved clinical outcome. In addition, im-
provements in implantation techniques to-
gether with enhanced antiplatelet regimens
have greatly reduced acute ischaemic events1
(< 2% when stents are implanted electively2
and approximately 5% in bailout situations3).
Both antirestenosis and antithrombotic aspects
must be addressed, however, if the stent’s
therapeutic potential is to be expanded even
further. Such improvements may be achieved
by enhancing the biocompatibility of the
implant.
Modification of a stent with respect to blood
and tissue compatibility can be achieved by
changing the stent material itself, or by
modifying the outer layer of the stent surface.
Changing the stent material may influence the
mechanical behaviour of the stent, but since
only the outer few micrometres of the metal
interact with the blood and tissue wall, it is
more practical to modify the outer stent surface
by coating it with a biocompatible molecule.
The ideal coating would be haemocompatible,
thereby not inducing stent thrombosis, and
could potentially reduce neointimal thickening
through improved tissue compatibility.
Previous studies have highlighted the success
of phosphorylcholine in improving the biocom-
patibility of surfaces.4–7 In our study the
phosphorylcholine coating applied to a metallic
coronary stent (fig 1) consists of a copolymer of
laurylmethacrylate and methacryloylphospho-
rylcholine, the latter as the phosphorylcholine
component.8 The zwitterionic head group of
phosphorylcholine provides a hydrophilic sur-
face while retaining an overall neutral charge
(fig 2). The phosphorylcholine head group that
is held responsible for improving biocompat-
ibility accounts for a small part of the coating,
while the majority of the coating consists of
components to give the required adhesion to
the metal surface. Although the phosphoryl-
choline component is based on a naturally
occurring phosphatidylcholine (a constituent
of the lipid bilayer of the cell membrane), the
current coating must be regarded as entirely
synthetic. As many synthetic polymers have
been associated with aggressive inflammatory
reactions and excessive neointimal growth,9 it
is important to study both the early and late
response to the coating.Figure 1 A macroscopic view of the divYsio stent.
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Our study therefore aimed to assess the
blood and tissue biocompatibility of the
phosphorylcholine coating, particularly its in-
fluence on the wound healing response, its
eVect on subsequent neointima formation, and
the vessel wall reaction to the synthetic coating,
in a porcine coronary stent model.
Methods
BALLOON EXPANDABLE STENT
The stent used in the current study is the bal-
loon expandable divYsio stent (Biocompatibles
Cardiovascular, Farnham, UK) (fig 1). This
stent, which is 15 mm long, has an interlocking
arrowhead design and is constructed of medi-
cal grade stainless steel 316L. Both phospho-
rylcholine coated and non-coated (bare) stents
were used in the study.
PHOSPHORYLCHOLINE COATING
The coating applied to the divYsio stent
consists of a copolymer of methacryloylphos-
phorylcholine and laurylmethacrylate. The
stents were dip coated from a solution of the
polymer in ethanol to give a coating that is
approximately 50 nm thick. The stents were
received precoated and sterilised from the
manufacturer.
ANIMAL CARE AND PREPARATION
Experiments were performed under the regula-
tions of the animal care committee of the Eras-
mus University Rotterdam and in accordance
with standard guidelines.
Experiments were performed in crossbred
Landrace Yorkshire pigs (30 kg) as previously
described.10 Starting one day before the proce-
dure and throughout the follow up period, all
animals received 300 mg carbasalatum calcium
(Ascal; Asta Medica BV, The Netherlands) by
mouth daily. After an overnight fast the animals
were sedated with 20 mg/kg ketamine hydro-
chloride. Anaesthesia was induced by 11 mg/kg
thiopental and, following endotracheal intuba-
tion, the pigs were connected to a ventilator
that administered a mixture of oxygen and
nitrous oxide (1:2, vol/vol). Anaesthesia was
maintained with 1–2.5 vol % isoflurane.
Antibiotic prophylaxis was administered by an
intramuscular injection of a preparation con-
taining 200 mg procaine benzylpenicillin and
250 mg dihydrostreptomycin sulfate per ml
(Streptoprocpen; AUV, Cuijk, The Nether-
lands) at a dose of 1 ml per 25 kg bodyweight
as a standard laboratory procedure. Under
sterile conditions an arteriotomy of the left
carotid artery was performed and an 8F intro-
duction sheath was placed. After measurement
of arterial blood pressure and heart rate, and
withdrawal of an arterial blood sample for the
measurement of activated partial thromboplas-
tin time (APTT), blood gases, and acid base
balance (settings of the ventilator corrected, if
necessary), 10 000 IU heparin sodium and
250 mg aspirin were administered through the
sheath and an 8F guiding catheter was
advanced to the ascending aorta. An APTT of
at least three times baseline was maintained
throughout the procedure. Coronary angio-
graphy was performed using a contrast agent
(Omnipaque; Nycomed Ireland Ltd, Cork, Ire-
land), and quantitative angiographic analysis
was performed using the edge detection
method (Cardiovascular Measurement Sys-
tem; Medis Inc, Nuenen, The Netherlands).11
STENT IMPLANTATION
From the angiograms, a coronary segment
with a diameter of 2.5–3.5 mm was selected in
the proximal left anterior descending coronary
artery (LAD), left circumflex coronary artery
(LCX), or right coronary artery (RCA), using
online quantitative coronary angiography.
Stents were randomised and implanted in a
paired fashion in separate coronary arteries.
While a preference was given for the LAD/
LCX (14 animals), stents were also implanted
in the LAD/RCA (one animal) and LCX/RCA
(one animal). Because of vessel size or tapering
in the remaining nine animals, stents were
implanted in single vessels (tables 1 and 2).
Side branches and curved coronary artery
segments were not avoided. A phosphorylcho-
line coated or non-coated stent was crimped
onto a deflated balloon and advanced over a
0.014 inch steerable guidewire to the prese-
lected site for implantation. The balloon was
then inflated for 30 seconds (mean inflation
pressure 9 atm), deflated, and negative pres-
sure maintained for 60 seconds. Matched
Figure 2 Schematic representation of the phosphorylcholine coating applied to the divYsio
stent (modified from Campbell and colleagues8).
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Table 1 Distribution of stents in coronary vessel pairs at
diVerent time points
Vessel pairs 5 days 4 weeks 12 weeks
LAD/LCX 5 4 5
LAD/RCA 1 0 0
LCX/RCA 0 1 0
LAD only 0 3 4
LCX only 0 0 2
Table 2 Distribution of coated and non-coated stents in
coronary arteries at diVerent time points
LAD LCX RCA
5 days
Coated 4 2 0
Non-coated 3 2 1
4 weeks
Coated 5 1 0
Non-coated 2 4 1
12 weeks
Coated 5 3 0
Non-coated 4 4 0
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implantation of the stent and artery was
performed, such that the intended balloon:ar-
tery ratio was as near to 1 as possible. The
catheter was then slowly withdrawn while leav-
ing the stent in place. After repeat angiography,
the guiding catheter and the introducer sheath
were removed, the arteriotomy repaired, and
the skin closed in two layers. At the end of the
procedure, the animals were allowed to recover
and returned to the animal care facilities.
In total, 41 stents (20 coated, 21 non-coated)
were implanted into 25 animals; these animals
were assigned to three groups (tables 1 and 2)
to study the progress of wound healing and
neointima formation at five days, four weeks,
and 12 weeks.
FOLLOW UP ANGIOGRAPHY
The anaesthesia and catheterisation proce-
dures at follow up were similar to those
described above, while coronary angiography
was performed in the same projection, and
using identical settings of the radiographic
equipment, as during implantation.
MICROSCOPICAL EXAMINATION
After angiography at follow up, the thorax was
opened by a midsternal split and a lethal dose
of sodium pentobarbital was injected intrave-
nously, immediately followed by cross clamp-
ing of the ascending aorta. After puncturing the
aortic root above the coronary ostia, 300 ml of
saline was infused under a pressure of
150 cm H2O, followed by 500 ml of 2.5% glu-
taraldehyde in 0.15 mol/l cacodylatebuVer for
scanning electron microscopy (SEM) or
500 ml of 4% buVered formaldehyde for light
microscopy. The heart was then excised and
the coronary arteries dissected free from the
epicardial surface. The stented and adjacent
unstented (5 mm) segments were kept in fixa-
tive for at least 24 hours and thereafter were
further processed for light microscopy12 or for
SEM as previously described.10 For light
microscopy, stented vessels were embedded
intact in methylmethacrylate, sectioned, and
stained with haematoxylin and eosin as a
routine stain, and resorcin–fuchsin as an elastin
stain. Lectin histochemistry was performed to
confirm the identity of the regenerated
endothelium.13
MORPHOMETRY
Morphometric analysis of the neointimal
formation in vessels processed for light micros-
copy was performed in the proximal, middle,
and distal stent segment on elastin stained sec-
tions by tracing the external and internal elas-
tic laminae and the endothelial lining using a
microscopy image analysis system (Impak C,
Clemex vision Image analysis system; Clemex
Technologies, Quebec, Canada). The media
was defined as the layer between the internal
and external elastic laminae. The area between
the endothelial lining and the internal elastic
lamina was taken as the intima.
SCANNING ELECTRON MICROSCOPY AND
PLANIMETRY
SEM was performed to study endothelial
regrowth at five days. After fixation with 2.5%
glutaraldehyde in 0.15 mol/l cacodylate buVer,
the arteries were further processed as previously
described.10 Assessment of endothelial regrowth
was performed by studying eight areas in the
proximal, middle, and distal stent segments of
vessels by SEM. From photographs of these
areas, the stent struts were traced, the endothe-
lium marked, and the percentage endothelial
coverage of the stent struts quantified using
computer assisted planimetry.
STATISTICAL ANALYSIS
Data were analysed using Jandel Sigmastat sta-
tistical software, version 2.0 (Jandel Corpora-
tion). All data are expressed as mean (SD) or as
median (range). The angiographic and mor-
phometric data were evaluated by a two way
repeated measures analysis of variance
(ANOVA) and a two way ANOVA, respectively,
followed by a Student–Neuman Keuls test. A
value of p < 0.05 was considered significant.
Results
PROCEDURAL SUCCESS
A total of 20 phosphorylcholine coated and 21
non-coated stents (25 animals) were implanted
successfully. All animals survived the follow up
period without stent thrombosis or other
adverse events. In the four week group,
Table 3 Quantitative coronary angiography (QCA) at five days, four weeks, and 12
weeks, after implantation of the phosphorylcholine coated and non-coated stents
QCA pre
(mm)
QCA post
(mm)
QCA follow up
(mm) B:A ratio n
5 days
Coated 2.9 (0.5) 3.1 (0.3) 3.0 (0.3) 1.1 (0.1) 6
Non-coated 3.2 (0.3) 3.3 (0.3) 3.2 (0.3) 1.0 (0.0) 6
4 weeks
Coated 3.2 (0.2) 3.3 (0.2) 2.8 (0.5) 1.0 (0.1) 7
Non-coated 2.9 (0.4) 3.1 (0.2) 3.0 (0.3) 1.2 (0.2) 6
12 weeks
Coated 3.0 (0.3) 3.1 (0.5) 3.2 (0.5) 1.0 (0.1) 8
Non-coated 3.0 (0.3) 3.0 (0.3) 2.9 (0.4) 1.0 (0.1) 8
Data presented as mean (SD); B:A ratio, balloon:artery ratio; n, number of stented coronary
arteries.
Table 4 Morphometric analysis at four and 12 weeks after implantation of the coated and non-coated stents
Lumen area
(mm2)
Neointimal area*
(mm2)
Media area
(mm2)
Neointimal thickness
at stent struts* (mm)
Media thickness at
stent struts (mm)
Neointimal thickness
between stent struts (mm)
Media thickness between
stent struts (mm)
4 weeks
Coated (n = 7) 5.76 (1.63) 1.71 (0.67) 1.46 (0.55) 0.24 (0.09) 0.09 (0.04) 0.18 (0.08) 0.13 (0.03)
Non-coated (n = 6) 6.82 (2.27) 1.81 (0.99) 1.24 (0.11) 0.25 (0.13) 0.08 (0.02) 0.18 (0.13) 0.13 (0.02)
12 weeks
Coated (n = 8) 5.89 (1.37) 2.22 (1.54) 1.18 (0.29) 0.32 (0.22) 0.06 (0.02) 0.23 (0.18) 0.12 (0.04)
n = 6 1.38 (0.54)† 0.20 (0.08)† 0.14 (0.07)†
Non-coated (n = 8) 6.16 (1.79) 1.41 (0.77) 1.13 (0.15) 0.22 (0.12) 0.06 (0.01) 0.15 (0.11) 0.12 (0.02)
n = 7 1.19 (0.48)† 0.19 (0.07)† 0.12 (0.06)†
Data presented as mean (SD); *including area occupied by the stent strut; †data when aberrant results caused by rupture of external elastic lamina and excessive
inflammatory reaction have been excluded.
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however, there was one incidence of stent col-
lapse, where the excised stented vessel ap-
peared to be elliptical rather than round.
QUANTITATIVE ANGIOGRAPHIC MEASUREMENTS
Quantitative angiographic measurements are
summarised in table 3. With a mean balloon
diameter of 3.1 (0.3) mm at maximal pressure,
stent recoil was 2 (7)%. The results at five days,
four weeks, and 12 weeks showed no significant
diVerence in late loss (post versus follow up)
between the coated and non-coated groups.
There appeared to be a trend, however,
towards an increased late loss in the coated
group at four weeks which is explained by one
incidence of stent collapse in this group
(angiographic late loss then seems abnormally
large). Such a trend was not observed in the
morphometric results and therefore deemed
unimportant. Indeed, the neointimal thickness
in this group was identical to that of the control
group at four weeks (table 4).
GENERAL HISTOPATHOLOGY AND PERFORMANCE
OF THE STENT COATING
Histopathology at five days
In this group, two vessels (one animal: one
coated, one non-coated) were examined by
light microscopy and the remainder by SEM
for evaluation of endothelialisation. In the two
arteries examined by light microscopy the inti-
mal thickening consisted of organising throm-
bus or granulation tissue containing inflamma-
tory cells (macrophages, macrophage giant
cells, granulocytes) (fig 3A). In both vessels,
macrophage giant cells were frequently seen
surrounding the stent struts voids. In the
coated group, the purple stained coating was
still discernible in the stent strut voids and did
not appear to elicit an adverse inflammatory
response. Both arteries showed adhesion and
infiltration of leucocytes to an incomplete
endothelial layer, the identity of the endothe-
lium being confirmed by lectin histochemistry.
The medial and adventitial layers were normal.
In both the coated and non-coated groups
SEM showed an advanced but incomplete
endothelial covering, with macrophages fre-
quently occupying the areas that were devoid of
endothelium (fig 3B).
Histopathology at four weeks
At four weeks in both the coated and
non-coated groups, the asymmetric neointima
(fig 4) consisted of smooth muscle cells in an
extracellular matrix, covered by an endothelial
layer with some adherent leucocytes. Towards
the intimal/medial border zone the cellular
density was distinctly less and the cells were in
a haphazard orientation with some containing
thrombus remnants, inflammatory cells, and
foam cells. Macrophage giant cells were
observed surrounding the stent strut voids in
both groups. In areas of maximal intimal thick-
ening there was often abundant extracellular
matrix. The medial and adventitial layers were
only aVected by inflammation in the case of
medial ruptures or complete dissection (four
vessels: two coated, two non-coated), but these
inflammatory changes were discrete. In the
coated group, the purple stained coating in the
stent strut voids was discernible in five of the
seven vessels.
Histopathology at 12 weeks
In both groups the neointima consisted of
smooth muscle cells in an extracellular matrix
with an organisation similar to that observed in
the four week group, except that the intimal/
medial border zone sometimes contained acel-
lular areas. In this border zone, inflammation
and neovascularisation were observed con-
comitant with medial damage. Some diVuse
inflammatory infiltrates were seen in the
adventitia (three vessels). In the coated stented
arteries purple stained coating was still ob-
served in the stent strut voids in six out of eight
vessels (fig 5A).
MORPHOMETRY
Endothelialisation
At five days the percentage of endothelium
covering the stent struts was determined using
Figure 3 (A) Light microscopy of the intimal thickening at five days postimplant,
showing granulation tissue over the stent wire void (*), with occasional leucocytes
(arrowheads) attached to the endothelium (bar = 30 µm).NI, neointima;M,media;
haematoxylin and eosin. (B) SEM of a stent strut (S) at five days, showing an incomplete
endothelial lining (arrow), with leucocytes (arrowheads) and macrophages (*) occupying
areas devoid of endothelium (bar = 20 µm).
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SEM (fig 3B) and amounted to 91% (range
76–93%) for the coated stent and 92% (range
70–98%) for the non-coated stent, which was
not significantly diVerent.
Neointimal formation
The data for the four and 12 week study groups
are summarised in table 5. There is no signifi-
cant diVerence in intimal thickness and area
between the coated and non-coated stents at
four weeks. While every attempt was made to
implant the stents with minimal vascular dam-
age (balloon:artery ratio of approximately 1),
on three occasions stent implantation resulted
in excessive vascular damage, with a concomi-
tant inflammatory response in the 12 week
group. Analysis of this group was therefore
performed with (coated n = 8, non-coated
n = 8) and without (coated n = 6, non-coated
n = 7) inclusion of these vessels in an attempt
to ascertain whether the inflammatory reaction
somehow masked any small diVerences in inti-
mal thickness or area in this group. The results
in table 4 show that when the oversized vessels
are excluded from analysis, there is no
significant diVerence in the intimal thickness
and area between the phosphorylcholine
coated and non-coated groups at 12 weeks.
Discussion
Although coronary stenting is regarded as a
major success in interventional cardiology, the
problem of restenosis, and to a lesser extent
that of stent thrombosis, remain limiting
factors that restrict its use in a wider patient
population.
Clinically approved stents are all made of
metal. In an eVort to reduce the above
mentioned problems, coating the metal with a
molecule that mimics a biological, naturally
occurring molecule (a form of biological cam-
ouflage or biomimicry) has raised hopes that
these problems can be reduced or
eliminated.14 15 In this respect, our study
addressed the eVects of coating a stainless steel
metal stent with a synthetic polymer containing
a phosphorylcholine head group. Previous
work has shown its success in improving
biocompatibility of surgical equipment and
guide wires4–7 and in reducing neointimal
hyperplasia in synthetic vascular grafts in a
canine model.16
OBJECTIVE AND MAIN FINDINGS
The main objective of this study was to deter-
mine the biocompatibility of the phosphoryl-
choline coating over a period of up to 12 weeks,
comparing it to a non-coated equivalent. The
main finding was that the coating has an excel-
lent biocompatibility. The phosphorylcholine
coating did not induce stent thrombosis, had
no adverse eVect on the rate of re-
endothelialisation, and was present for the
duration of the study. The wound healing
response for the coated and non-coated stents
was similar at both four and 12 weeks.
ANIMAL MODEL AND INJURY
In the porcine model of oversized stent
implantation, the degree of vascular injury that
accompanies stent implantation induces a vari-
able amount of inflammation and neointimal
Figure 4 Overview (left) of a stented artery at four weeks showing an asymmetric
neointima (bar = 500 µm), with detail (right) showing cells in a haphazard orientation
with thrombus remnants (arrowhead) in the intimal/medial border zone (bar = 100 µm).
NI, neointima;M,media; A, adventitia; haematoxylin and eosin.
Figure 5 (A) Detail of purple stained coating (arrowheads) observed in the stent strut
void (*) 12 weeks after implantation of a phosphorylcholine coated stent (bar = 45 µm).
NI, neointima;M,media; haematoxylin and eosin. (B) Detail of the cut surface of a stent
strut from a non-implanted coated stent (bar = 20 µm). The phosphorylcholine coating
(arrow) seen at the strut edge is similar in appearance to that seen in A.Haematoxylin and
eosin.
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growth. In this respect, variation in vessel wall
response caused by the eVect of coatings and
the induced vessel injury are less easily
distinguished from one another. In our study,
therefore, we chose a matched size model for
stent implantation, which allowed us to detect
small diVerences in the vessel wall response to
the phosphorylcholine coating without being
overshadowed by a considerable response to
injury. In the 12 week group, however, three
stents were clearly oversized (two coated, one
non-coated). Inclusion of the morphometric
data for these animals would appear to suggest
that the neointima increased in the coated
group between four and 12 weeks. If the data
are excluded for those animals in which
oversized stents were implanted, however, then
there is normal regression of the neointima in
both groups at 12 weeks.
BLOOD BIOCOMPATIBILITY AND EARLY WOUND
HEALING
In a previous study using the stainless steel
Palmaz-Schatz stent (same material, diVerent
geometry and surface characteristics), stents
thrombosed irrespective of whether aspirin was
administered postoperatively.17 18 Absence of
thrombosis in our study in both the coated and
non-coated groups may be explained by the
fact that the geometry and/or surface charac-
teristics of the stent are such that it is inherently
less thrombogenic. In our animal model both
the stent and the phosphorylcholine coating
showed excellent blood compatibility.
Following stent implantation, it is desirable
that the vascular wall heals as quickly as possi-
ble, thereby incorporating the stent into the
vessel wall. Histological parameters of com-
pleted vessel wall healing are re-
endothelialisation and the progression of
granulation tissue to a mature neointima. In a
previous study, data suggested that a heparin
coating delayed re-endothelialisation at four
weeks, such that the neointimal thickening was
also aVected.17 We therefore used the rate of
endothelialisation as a parameter of the early
wound healing process. The eVect of the phos-
phorylcholine coating on wound healing and
neointimal formation after stenting is un-
known. Theoretically the phosphorylcholine
group might be expected to retard the rate of
re-endothelialisation since it inhibits the depo-
sition of plasma proteins onto the stent
surface.19 The absence of a protein layer may
make the stent surface less “attractive” for the
endothelial cells to grow on.20 In this model,
however, the percentage endothelial covering
after five days as assessed by planimetry was
similar in both the coated and non-coated
groups (91% v 92%). Therefore the phospho-
rylcholine coating did not delay the early
wound healing response.
TISSUE BIOCOMPATIBILITY
At four weeks there was no diVerence in
neointimal thickness between the coated and
non-coated groups (coated 0.14 (0.09) mm;
non-coated 0.15 (0.13) mm). These results
correlate with those from Kuiper and col-
leagues in so far that they also found no diVer-
ence in neointimal thickness between the
coated and non-coated stents.21 That study
restricted its follow up to 28 days only,
however. In studying the biocompatibility of
synthetic polymers it is important to study the
reaction at multiple time points, given the
potential for synthetic polymers to show
delayed inflammatory reactions. We therefore
studied the vessel wall reaction to the coating at
multiple time points up to 12 weeks.
At 12 weeks in both the phosphorylcholine
coated and non-coated groups, a morphologi-
cally mature neointima was formed. In the area
of the stent strut voids macrophage giant cells
were occasionally associated with the implant.
Such cells were observed in both coated and
non-coated groups, and are part of the normal
reaction to foreign implants. In the phospho-
rylcholine group, evidence of the coating was
observed in the stent strut voids up to three
months postimplant. Given that such purple
stained material is similar to that observed
when stained cross sections of a non-implanted
phosphorylcholine coated stent were examined
for the presence of the coating (fig 5B), we
conclude that this coating remains present up
Table 5 Coated stents
Author Stent Animal model Coating Control
Neointimal thickness
Duration
(weeks)Coated Control
– divYsio Porcine coronary, matched PC Bare stent
Bare stent
0.14 (0.09)§
0.10 (0.08)§
0.15 (0.13)§
0.09 (0.07)§
4
12
Kuiper21 Palmaz-Schatz Rabbit iliac, porcine coronary, matched PC Bare stent 0.20 (0.05)
0.44 (0.27)
0.23 (0.11)
0.47 (0.38)
4
4
van der
Giessen9
Wiktor Porcine coronary, matched PGLA
PEO
Bare stent
Bare stent
0.46 (0.18)
2.36 (0.60)
0.08 (0.03)
0.38 (0.17)
4
4
Hardhammer17 Palmaz-Schatz Porcine coronary, matched Heparin Bare stent
Bare stent
0.26 (0.10)
0.15 (0.06)
0.11 (0.04)
0.20 (0.05)
4
12
van der
Giessen26
Wallstent Porcine coronary, matched Biogold Bare stent 0.11
(0.04–0.17)†
0.10
(0.07–0.19)†
12
de Scheerder27 Not described Porcine coronary, oversized injury model POP/MPD POP stent 0.99 (0.28) 1.74 (0.84) 6
Cox28 Cook Porcine coronary, oversized injury model CEL/HEP/MET Bare stent – – 4
LincoV23 Wiktor Porcine coronary, oversized injury model HMWPLLA/DEX PLLA stent
Bare stent
0.79 (0.44)‡ 0.81 (0.23)‡
0.88 (0.31)‡
4
Aggarwal34 Cook Rabbit iliac, balloon injury model CEL/GPIIb/IIIa CEL ± anti
CMV
0.12 (0.04) 0.11 (0.07) 4
PC, phosphorylcholine; PGLA, polyglycolic/lactic acid; PEO, polyethyleneoxide; POP/MPD, polyorganophosphazene/methylpredisnolone; CEL/HEP/MET,
cellulose/heparin/methotrexate; HMWPLLA/DEX, high molecular weight poly-L lactic acid/dexamethasone; CMV, cytomegalovirus.
*Representative values for the best and worst performing polymers are given; †range; ‡values calculated from fig 6 in LincoV et al23; §for comparative purposes, the
thickness of the wire struts have been deducted from the data.
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to three months postimplantation. Indeed, our
findings have recently been corroborated by
Tolhurst who reported results showing that the
coating does not degrade and is stable up to six
months postimplantation.22 (Although the
phosphorylcholine coating on the stent is thin,
some swelling of the polymer occurs during
histological processing, such that it is visible
with light microscopy.) The fact that there was
a minimal inflammatory response to the
coating is a reassuring finding, since the phos-
phorylcholine coating is composed of synthetic
polymers and to date most synthetic materials
used to coat stents have often been associated
with intense inflammatory reactions and vari-
able neointimal growth.9 23–25
PHOSPHORYLCHOLINE COMPARED TO OTHER
COATINGS
Table 5 compares the neointimal thickness
from our study with those of other studies
using coated stents in both matched sized
models and oversized injury models.
In matched sized models of stent
implantation,9 17 26 when results of neointimal
thickness for the control stents are grouped, the
range of neointimal thickness is 0.10–
0.40 mm. The thickness of the coated group is
well within this range. Indeed the neointimal
thickness of the phosphorylcholine coated
group is comparable to that of the heparin
coated Palmaz-Schatz stent, which was ex-
pected to be approved by the US Food and
Drug Administration in 1999. Given that the
phosphorylcholine coating can be regarded as a
synthetic polymer, the results appear to be
considerably better than those using PGLA
and PEO strips (among others) applied to the
Wiktor stent.9
In the 12 week phosphorylcholine coated
group, two stents were oversized at implanta-
tion. If the mean neointimal thickness for these
vessels (0.62 (0.11) mm) is compared to the
grouped range in the oversized injury group
(0.11–1.74 mm),23 27 28 then the phosphoryl-
choline result (oversized group) again falls
within this range. In the study of de Scheerder,
the neointimal thickness of the eluting stent is
reduced compared to the control POP stent
(0.99 (0.28) mm v 1.74 (0.84) mm)27; this
thickness, however, is still almost twice that of
the neointimal thickness for the oversized
coated stents in our study (0.62 (0.11) mm v
0.99 (0.28) mm). Therefore, in comparison to
other studies of coated stents and irrespective
of the model used, the synthetic phosphoryl-
choline coating performs well.
POTENTIAL OF THE COATING
The complex processes that lead to restenosis
can probably never be resolved by a single
treatment alone. The possibility of using a
coated stent as a carrier of drugs has therefore
great therapeutic potential. To date studies
involving synthetic polymer coated stents can
be divided into those used: (a) to explore the
potential of various materials as polymer stent
coatings9 29–31; (b) for in vitro drug release
kinetic studies32 33; and (c) for in vivo eYciency
studies of local drug delivery to the vessel
wall.23 27 34 The results of such experiments
have generally shown that while drug release is
feasible, the drug may be eVective in reducing
only the unwanted side eVects of the polymer
used, but not in reducing neointimal hyperpla-
sia per se. In the present study the coating
remained present up to 12 weeks postimplant,
without excessive neointimal growth (com-
pared to the control). While the amount of
polymer remaining cannot be quantified in this
study, and it cannot be ascertained if there is a
gradient of polymer depletion over time, the
long term therapeutic potential of this particu-
lar coating in its present form is significantly
improved over currently available synthetic
polymer stent coatings. Such findings suggest
that this polymer can potentially be used as a
vehicle for local drug delivery, and initial drug
release studies are underway using this phos-
phorylcholine coated stent. By controlling the
physiochemical properties of the coating (cross
linked density, water content, isoelectric point,
molecular weight between cross links) the stent
coating can be tailored to the specific drugs
under investigation.
CONCLUSION
Both phosphorylcholine coated and non-
coated stents were implanted with a 100% suc-
cess rate without incidence of acute stent
thrombosis, despite an antiplatelet regimen of
only aspirin. Phosphorylcholine applied to the
stent as a coating does not interfere with
endothelialisation as measured at five days after
implantation. During the subsequent process
of wound healing, the coated and non-coated
stents elicit a tissue response that is similar in
nature. The only observed diVerence between
the two stents is the presence of the phospho-
rylcholine coating in the stent strut voids up to
12 weeks after implantation. Given the long
term presence of a coating that shows no
adverse inflammatory reaction, the phospho-
rylcholine coating shows potential as a suitable
candidate for local drug delivery.
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